A standardized combination of
📄 Abstract
One hundred participants aged 40-65 with subjective complaints of poor memory were randomized into two groups: 300 mg of LN19184 or placebo, once daily for 120 days. At baseline and days 15, 30, 60, and 120, two neuropsychological batteries, the Rey's Auditory Verbal Learning Test (RAVLT) and the Cambridge Neuropsychological Test (CANTAB), were used to assess cognitive function, and the Athens Insomnia Scale was used to evaluate sleep quality. Serum BDNF levels and safety parameters were also assessed. LN19184 improved each measured RAVLT outcome compared to placebo. Supplementation improved proactive interference ( This pilot trial provides early empirical evidence demonstrating that a novel extract blend of Clinicaltrials.gov, identifier CTRI/2020/08/027368.